Effects of peritoneal dialysis solutions on the peritoneal membrane: Clinical consequences

Peritoneal Dialysis International

Volumn 25, Issue SUPPL. 3, 2005, Pages

  Witowski, Janusz ^a,b   Jörres, Achim ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AGE; Biocompatibility; CA125; Glucose degradation products; Peritoneal dialysis fluids

Indexed keywords

'BALANCE'; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BICAVERA; CA 125 ANTIGEN; GAMBROSOL TRIO; GLUCOSE DEGRADATION PRODUCT; NITRIC OXIDE SYNTHASE; PERITONEAL DIALYSIS FLUID; PHYSIONEAL; VASCULOTROPIN;

BIOCOMPATIBILITY; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL STUDY; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG EFFICACY; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; MEMBRANE PERMEABILITY; MEMBRANE STRUCTURE; MESOTHELIUM CELL; NONHUMAN; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEUM; PH MEASUREMENT; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; REVIEW; TISSUE REGENERATION; ULTRAFILTRATION;

EID: 21244437172     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502503s08     Document Type: Review

References (23)

1. Aufricht C, Endemann M, Bidmon B, Arbeiter K, Mueller T, Regele H, et al. Peritoneal dialysis fluids induce the stress responsein human mesothelial cells. Perit Dial Int 2001; 21:85-8.
2. Wieslander AP, Kjellstrand PT, Rippe B. Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Perit Dial Int 1995; 15(7 Suppl):S52-9.
3. Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD. Effectof lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interteukin-6 and prostaglandin synthesis. Kidney Int 1995; 47:282-93.
4. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, et al. Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration. Kidney Int 2003; 64:1854-66.
5. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
6. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-38.
7. Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004; 19:2101-6.
8. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
9. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2OO3; 63:298-305.
10. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischets-rieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
11. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003; 14:2632-8.
12. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21:560-7.
13. Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jörres A, Lage C, et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant 2004; 19:917-24.
14. Horiuchi T, Miyamoto K, Miyamoto S, Fujita M, Sano N, Minamiyama K, et al. Image analysis of remesothelialization following chemical wounding of cultured human peritoneal mesothelial cells: the role of hyaluronan synthesis. Kidney Int 2003; 64:2280-90.
15. Wieczorowska-Tobis K, Brelinska R, Witowski J, Passlick-Deetjen J, Schaub TP, Schilling H, et al. Evidence for less irritation tothe peritoneal membranein rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 2004; 24:48-57.
16. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, et al. In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280:1408-14.
17. Mortier S, Faict D, Schalkwijk CG, Lameire N H, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257-65.
18. Park SH, Lee EG, Kim IS, Kim YJ, Cho DK, Kim YL. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat. Perit Dial Int 2004; 24:115-22.
19. Inagi R, Miyata T, YamamotoT, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS lett 1999; 463:260-4.
20. Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 2002; 61:570-8.
21. Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M, et al. Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats. Perit Dial Int 2004; 24:37-47.
22. Miyata T, Horie K, Ueda Y, Fujita Y, Izuhara Y, Hirano H, et al. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58:425-35.
23. van de KJ, Schalkwijk CG, Konings CJ, Cheriex EC, van der Sande FM, Scheffer PG, et al. N(epsilon)-(carboxymethyl)lysine, N(epsilon)-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function: a study in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19:910-16.